Resumption of methimazole after 131I therapy of hyperthyroid diseases: Effect on thyroid function and volume evaluated by a randomized clinical trial

European Journal of Endocrinology

Volumn 149, Issue 6, 2003, Pages 485-492

  Bonnema, Steen J ^a   Bennedbæk, Finn N ^a   Gram, Jeppe ^a   Veje, Annegrete ^a   Marving, Jens ^a   Hegedüs, Laszlo ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; IODINE 131; LEVOTHYROXINE; THIAMAZOLE; THYROXINE; ANTITHYROID AGENT; RADIOACTIVE IODINE; RADIOPROTECTIVE AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG WITHDRAWAL; ECHOGRAPHY; EUTHYROIDISM; FEMALE; FOLLOW UP; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIATION PROTECTION; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; THYROID FUNCTION; THYROID WEIGHT; THYROIDECTOMY; THYROTOXICOSIS; THYROXINE BLOOD LEVEL; TOXIC GOITER; TREATMENT OUTCOME; AGED; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NODULAR GOITER;

AGED; ANTITHYROID AGENTS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; GOITER, NODULAR; GRAVES DISEASE; HUMANS; IODINE RADIOISOTOPES; MALE; METHIMAZOLE; MIDDLE AGED; RADIATION-PROTECTIVE AGENTS; RECURRENCE; TREATMENT OUTCOME;

EID: 0346724716     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1490485     Document Type: Article

References (37)

1. Solomon B, Glinoer D, Lagasse R & Wartofsky L. Current trends in the management of Graves' disease. Journal of Clinical Endocrinology and Metabolism 1990 70 1518-1524.
2. Imamura M, Aoki N, Saito T, Ohno Y, Maruyama Y, Yamaguchi J et al. Inhibitory effects of antithyroid drugs on oxygen radical formation in human neutrophils. Acta Endocrinologica 1986 112 210-216.
3. Connell JM, Hilditch TE, Robertson J, Coghill G & Alexander WD. Radioprotective action of carbimazole in radioiodine therapy for thyrotoxicosis - influence of the drug on iodine kinetics. European Journal of Nuclear Medicine 1987 13 358-361.
4. Crooks J, Buchanan WW, Wayne EJ & MacDonald E. Effect of pretreatment with methylthiouracil on results of 131I therapy. British Medical Journal 1960 16 151-154.
5. Clerc J, Izembart M, Dagousset F, Jais JP, Heshmati HM, Chevalier A et al. Influence of dose selection on absorbed dose profiles in radioiodine treatment of diffuse toxic goiters in patients receiving or not receiving carbimazole. Journal of Nuclear Medicine 1993 34 387-393.
6. Hancock LD, Tuttle RM, LeMar H, Bauman J & Patience T. The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves' disease. Clinical Endocrinology 1997 47 425-430.
7. Imseis RE, Vanmiddlesworth L, Massie JD, Bush AJ & Vanmiddlesworth NR. Pretreatment with propylthiouracil but not methimazole reduces the therapeutic efficacy of iodine-131 in hyperthyroidism. Journal of Clinical Endocrinology and Metabolism 1998 83 685-687.
8. Reynolds LR & Kotchen TA. Antithyroid drugs and radioactive iodine. Fifteen years' experience with Graves' disease. Archives of Internal Medicine 1979 139 651-653.
9. Sabri O, Zimny M, Schulz G, Schrechenberger M, Reinartz P, Willmes K et al. Success rate of radioiodine therapy in Graves' disease: the influence of thyrostatic medication. Journal of Clinical Endocrinology and Metabolism 1999 84 1229-1233.
10. Turton DB, Silverman ED & Shakir KM. Time interval between the last dose of propylthiouracil and I-131 therapy influences cure rates in hyperthyroidism caused by Graves' disease. Clinical Nuclear Medicine 1998 23 810-814.
11. Tuttle RM, Patience T & Budd S. Treatment with propylthiouracil before radioactive iodine therapy is associated with a higher treatment failure rate than therapy with radioactive iodine alone in Graves' disease. Thyroid 1995 5 243-247.
12. Allahabadia A, Daykin J, Sheppard MC, Gough SC & Franklyn JA. Radioiodine treatment of hyperthyroidism - prognostic factors for outcome. Journal of Clinical Endocrinology and Metabolism 2001 86 3611-3617.
13. Alexander EK & Larsen PR. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease. Journal of Clinical Endocrinology and Metabolism 2002 87 1073-1077.
14. Velkeniers B, Cytryn R, Vanhaelst L & Jonckheer MH. Treatment of hyperthyroidism with radioiodine: adjunctive therapy with antithyroid drugs reconsidered. Lancet 19881 1127-1129.
15. Jarløv AE, Christensen E, Hegedüs L, Kristensen LØ., Nygaard B & Hansen JM. Factors associated with recurrence of hyperthyroidism after 131I treatment: the inadvertent influence of antithyroid drug administration after 131I treatment of hyperthyroidism. Thyroidology 1997 9 55-59.
16. Marcocci C, Gianchecchi D, Masini I, Golia F, Ceccarelli C, Bracci E et al. A reappraisal of the role of methimazole and other factors on the efficacy and outcome of radioiodine therapy of Graves' hyperthyroidism. Journal of Endocrinological Investigation 1990 13 513-520.
17. Nakazato N, Yoshida K, Mori K, Kiso Y, Sayama N, Tani JI et al. Antithyroid drugs inhibit radioiodine-induced increases in thyroid autoantibodies in hyperthyroid Graves' disease. Thyroid 1999 9 775-779.
18. Kung AW, Yau CC & Cheng AC. The action of methimazole and L-thyroxine in radioiodine therapy: a prospective study on the incidence of hypothyroidism. Thyroid 1995 5 7-12.
19. Perros P. Anti-thyroid drug treatment before radioiodine in patients with Graves' disease: soother or menace? Clinical Endocrinology 2000 53 1-2.
20. Braga M, Walpert N, Burch HB, Solomon BL & Cooper DS. The effect of methimazole on cure rates after radioiodine treatment for Graves' hyperthyroidism: a randomized clinical trial. Thyroid 2002 12 135-139.
21. Andrade VA, Gross JL & Maia AL. The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves' hyperthyroidism: one-year follow-up of a prospective, randomized study. Journal of Clinical Endocrinology and Metabolism 2001 86 3488-3493.
22. Hegedüs L. Thyroid size determined by ultrasound. Influence of physiological factors and non-thyroidal disease (Thesis). Danish Medical Bulletin 1990 37 249-263.
23. Kok SW, Smit JW, de Craen AJ, Goslings BM, Eck-Smit BL & Romijn JA. Clinical outcome after standardized versus dosimetric radioiodine treatment of hyperthyroidism: an equivalence study. Nuclear Medicine Communications 2000 21 1071-1078.
24. Jarløv AE, Hegedüs L, Kristensen LØ, Nygaard B & Hansen JM. Is calculation of the dose in radioiodine therapy of hyperthyroidism worth while? Clinical Endocrinology 1995 43 325-329.
25. Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC & Cowden EA. A randomized comparison of radioiodine doses in Graves' hyperthyroidism. Journal of Clinical Endocrinology and Metabolism 2003 88 978-983.
26. Van Isselt JW, de Klerk JM, Koppeschaar HP & Van Rijk PP. Iodine-131 uptake and turnover rate vary over short intervals in Graves' disease. Nuclear Medicine Communications 2000 21 609-616.
27. Catargi B, Leprat F, Guyot M, Valli N, Ducassou D & Tabarin A. Optimized radioiodine therapy of Graves' disease: analysis of the delivered dose and of other possible factors affecting outcome. European Journal of Endocrinology 1999 141 117-121.
28. Howarth D, Epstein M, Lan L, Tan P & Booker J. Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study. European Journal of Nuclear Medicine 2001 28 1489-1495.
29. Ahmad AM, Ahmad M & Young ET. Objective estimates of the probability of developing hypothyroidism following radioactive iodine treatment of thyrotoxicosis. European Journal of Endocrinology 2002 146 767-775.
30. Körber C, Schneider P, Korber-Hafner N, Hanscheid H & Reiners C. Antithyroid drugs as a factor influencing the outcome of radioiodine therapy in Graves' disease and toxic nodular goitre? European Journal of Nuclear Medicine 2001 28 1360-1364.
31. Nygaard B, Hegedüs L, Gervil M, Hjalgrim H, Hansen BM, Søe-Jensen P et al. Influence of compensated radioiodine therapy on thyroid volume and incidence of hypothyroidism in Graves' disease. Journal of Internal Medicine 1995 238 491-497.
32. Nygaard B, Hegedüs L, Nielsen KG, Ulriksen P & Hansen JM. Long-term effect of radioactive iodine on thyroid function and size in patients with solitary autonomously functioning toxic thyroid nodules. Clinical Endocrinology 1999 50 197-202.
33. Nygaard B, Hegedüs L, Ulriksen P, Nielsen KG & Hansen JM. Radioiodine therapy for multinodular toxic goiter. Archives of Internal Medicine 1999 159 1364-1368.
34. Nygaard B, Knudsen JH, Hegedüs L, Veje A & Hansen JE. Thyrotropin receptor antibodies and Graves' disease, a side-effect of 131I treatment in patients with nontoxic goiter. Journal of Clinical Endocrinology and Metabolism 1997 82 2926-2930.
35. Meier DA, Brill DR, Becker DV, Clarke SE, Silberstein EB, Royal HD et al. Procedure guideline for therapy of thyroid disease with (131)iodine. Journal of Nuclear Medicine 2002 43 856-861.
36. Andrade VA, Gross JL & Maia AL. Effect of methimazole pretreatment on serum thyroid hormone levels after radioactive treatment in Graves' hyperthyroidism. Journal of Clinical Endocrinology and Metabolism 1999 84 4012-4016.
37. Burch HB, Solomon BL, Cooper DS, Ferguson P, Walpert N & Howard R. The effect of antithyroid drug pretreatment on acute changes in thyroid hormone levels after (131)I ablation for Graves' disease. Journal of Clinical Endocrinology and Metabolism 2001 86 3016-3021.